Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
Feb. 25, 2021—A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes.
Jan. 8, 2018—A comprehensive, multidisciplinary clinic serving patients with Prader-Willi syndrome recently opened at Monroe Carell Jr. Children’s Hospital at Vanderbilt. Prader-Willi syndrome (PWS) is a complex genetic disorder that affects appetite, growth, metabolism, cognitive function and behavior. It is characterized by the inability to achieve satiety, developmental delays and intellectual disability, short stature, behavioral concerns, sleep...
Dec. 22, 2016—A mutation associated with epilepsy and autism also is responsible for a “pale eye” trait in two rare genetic disorders, Angelman syndrome and Prader-Willi syndrome, neuroscientists at Vanderbilt University Medical Center reported this week.
Aug. 25, 2016—Children with Prader-Willi Syndrome who received growth hormone treatment had cognitive advantages compared to untreated patients.